Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products

The Associated Press
Thursday 05 December 2024 23:10 GMT

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.

Lilly said Thursday it will expand a Kenosha County, Wisconsin, factory it bought early this year, and the investment will help meet growing demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound.

Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter.

The drugmaker plans to start construction of the expansion next year.

Lilly also announced other multibillion-dollar manufacturing expansion projects near its Indianapolis headquarters earlier this year.

Eli Lilly and Co. said Thursday that it has slated more than $23 billion to construct, expand or acquire manufacturing sites worldwide since 2020.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in